Manufacturing resilience: antibody developers adapt to supply-demand shifts

COVID has thrown a wrench into supply and demand curves for raw materials and manufacturing slots that has forced biotechs developing antibody therapies to adapt quickly to keep programs on track. 

The capacity crunch for antibody-based therapies isn’t new to the COVID era, but its exacerbation has accelerated adoption of strategies that will help companies remain flexible in the long term. ...